Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

NCT06603623 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT06603623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06603623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2024
Completion date
March 28, 2025
Enrollment
647 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

migraine